EU's CHMP Delays Decision On Actos, Restricts Use Of An NSAID And Cytoprotective
This article was originally published in The Pink Sheet Daily
Executive Summary
Europe's top regulatory advisory panel wants further analysis of Actos' link with bladder cancer, but recommends limiting indications for the NSAID nimesulide and adding contraindications for the cytoprotective dexrazoxane.
You may also be interested in...
Deals Of The Week: Pfizer Management Updates Thoughts On Split
Pfizer top management hasn’t yet decided whether it will divide in two or stop at a “virtual split.” Plus updates on Lundbeck/Otsuka, Shire/SARcode, AstraZeneca/Actavis, and more.
Actos To Get Bladder Cancer Warnings In Europe And A Chance At A Rebound
EU's top scientific advisory panel says Takeda's diabetes drug should have new contraindications and warnings about bladder cancer added to its prescribing information.
Actos To Get Bladder Cancer Warnings In Europe And A Chance At A Rebound
EU's top scientific advisory panel says Takeda's diabetes drug should have new contraindications and warnings about bladder cancer added to its prescribing information.